PharmaCyte Biotech, Inc..
PMCB.US | Research and experimental development on natural sciences and engineering
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer and diabetes using its Cell-in-a-Box technology. The company's lead product candidate is a therapy for pancreatic cancer, where genetically engineered cells are encapsulated and implanted near the...Show More
Better Health for All
20
PharmaCyte Biotech's entire business is devoted to developing cellular therapies for cancer and diabetes, indicating a 95-97% focus on health improvement.
1
The company's R&D budget is 100% allocated to health improvement, as evidenced by its sole focus on developing cellular therapies and conducting stability studies for its clinical trial product candidate, CypCaps™.
2
However, the company's Investigational New Drug Application (IND) for its Phase 2b clinical trial in pancreatic cancer was placed on clinical hold by the FDA in October 2020, indicating notable safety incidents or concerns.
3
Fair Money & Economic Opportunity
0
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies, not a financial institution. The 'Fair Money & Economic Opportunity' value specifically assesses companies involved in lending, insuring, moving, or storing money. The provided article, which discusses patient assistance programs from AstraZeneca (not PMCB.US), does not contain any information about PMCB.US's involvement in financial services or economic opportunity initiatives.
1
Therefore, no KPIs under this value can be scored based on the evidence provided.
Fair Pay & Worker Respect
0
No information regarding PharmaCyte Biotech, Inc.'s fair pay and worker respect practices could be extracted from the provided article, as access to the content was throttled.
1
Fair Trade & Ethical Sourcing
0
No quantitative data relevant to Fair Trade & Ethical Sourcing KPIs was found in the provided articles for PharmaCyte Biotech, Inc. explicitly states a lack of information across all relevant metrics, and the remaining articles were inaccessible due to throttling, preventing any assessment against the rubric's criteria.
1
Honest & Fair Business
0
No evidence available to assess PharmaCyte Biotech, Inc. on Honest & Fair Business.
Kind to Animals
-70
The company is conducting animal studies, including a pilot study with 2 pigs and a planned full-scale study with 90 pigs, to satisfy FDA requirements for lifting a clinical hold on a planned clinical trial.
1
Safety testing of Melligen cells in mice was also conducted.
2
While the company's scientific consultants have sought permission to forego the large animal study, arguing that human clinical trial data supersedes animal study data, they are proceeding with the pig study.
3
The Consolidated Appropriations Act for 2023 specifies that nonclinical testing for drugs and biologics may, but is not required to, include in vivo animal testing, allowing for various in vitro, in silico, or other human/non-human biology-based tests.
4
Despite this, the company is proceeding with animal tests.
5
The company is working to address issues raised by the FDA to have the clinical hold removed, but there is no public position on broader animal welfare legislation or active advocacy for higher standards.
6
No War, No Weapons
0
PharmaCyte Biotech's core business focuses on developing cellular therapies for cancer treatment, with no apparent connection to war, weapons, or conflict. The company's activities are centered around medical research and pharmaceutical development
1
. There is no evidence to suggest that PharmaCyte derives revenue from arms contracts, develops dual-use technologies with military applications, or engages in sales to embargoed regimes
2
,
3
. The company's supply chain primarily involves pharmaceutical ingredients and research equipment, which are unlikely to be associated with the defense industry. Insufficient evidence exists to provide a score other than zero.
Planet-Friendly Business
0
No specific, quantitative data points for PharmaCyte Biotech, Inc. (PMCB.US) were found in the provided articles that directly correspond to the defined KPIs for Planet-Friendly Business. The articles primarily discuss general industry trends and benchmarks for the biotechnology and pharmaceutical sector, which cannot be attributed to PMCB.US. One article mentioned an 'SDG Transparency Score' for PharmaCyte Biotech Inc., but this metric is not a KPI in the rubric.
1
Respect for Cultures & Communities
0
No evidence available to assess PharmaCyte Biotech, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess PharmaCyte Biotech, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific data regarding PharmaCyte Biotech, Inc.'s waste management, sustainable products, or circular economy metrics was found in the provided articles.
1